ProMIS Neurosciences Inc (PMN.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:PMN - CA74346M4065 - Common Stock
6 CAD
-0.24 (-3.85%)
Overall PMN gets a fundamental rating of 0 out of 10. We evaluated PMN against 23 industry peers in the Biotechnology industry. PMN may be in some trouble as it scores bad on both profitability and health. PMN has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- In the past year PMN has reported negative net income.
- PMN had a negative operating cash flow in the past year.
1.2 Ratios
- PMN has negative profitability rations, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- PMN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- PMN has more shares outstanding than it did 1 year ago.
- PMN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- Based on the Altman-Z score of -17.22, we must say that PMN is in the distress zone and has some risk of bankruptcy.
- PMN has a worse Altman-Z score (-17.22) than 70.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -17.22 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- PMN has a Current Ratio of 0.51. This is a bad value and indicates that PMN is not financially healthy enough and could expect problems in meeting its short term obligations.
- PMN has a worse Current ratio (0.51) than 70.97% of its industry peers.
- A Quick Ratio of 0.51 indicates that PMN may have some problems paying its short term obligations.
- PMN's Quick ratio of 0.51 is on the low side compared to the rest of the industry. PMN is outperformed by 70.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.51 | ||
| Quick Ratio | 0.51 |
3. Growth
3.1 Past
- PMN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -203.88%.
- The Revenue for PMN has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-203.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-85.38%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
3.2 Future
- PMN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.72% yearly.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-11.65%
EPS Next 2Y5.66%
EPS Next 3Y-5.37%
EPS Next 5Y5.72%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- PMN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year PMN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- PMN's earnings are expected to decrease with -5.37% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.66%
EPS Next 3Y-5.37%
5. Dividend
5.1 Amount
- No dividends for PMN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:PMN (7/21/2023, 7:00:00 PM)
6
-0.24 (-3.85%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.03%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap51.48M
Revenue(TTM)N/A
Net Income(TTM)-20.93M
Analysts80
Price Target26.52 (342%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)1.29%
EPS NY rev (3m)1.29%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.5
EYN/A
EPS(NY)-2.43
Fwd EYN/A
FCF(TTM)-2.54
FCFYN/A
OCF(TTM)-2.54
OCFYN/A
SpS0
BVpS-0.95
TBVpS-0.96
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.51 | ||
| Quick Ratio | 0.51 | ||
| Altman-Z | -17.22 |
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)193.61%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-203.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-85.38%
EPS Next Y-11.65%
EPS Next 2Y5.66%
EPS Next 3Y-5.37%
EPS Next 5Y5.72%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-113.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-22.81%
EBIT Next 3Y-8.76%
EBIT Next 5Y8.97%
FCF growth 1Y-307.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-318.48%
OCF growth 3YN/A
OCF growth 5YN/A
ProMIS Neurosciences Inc / PMN.CA FAQ
What is the fundamental rating for PMN stock?
ChartMill assigns a fundamental rating of 0 / 10 to PMN.CA.
Can you provide the valuation status for ProMIS Neurosciences Inc?
ChartMill assigns a valuation rating of 0 / 10 to ProMIS Neurosciences Inc (PMN.CA). This can be considered as Overvalued.
What is the profitability of PMN stock?
ProMIS Neurosciences Inc (PMN.CA) has a profitability rating of 0 / 10.
Can you provide the financial health for PMN stock?
The financial health rating of ProMIS Neurosciences Inc (PMN.CA) is 1 / 10.